(CercleFinance.com) – Moderna announced that the Data and Safety Monitoring Board (DSMB) for the RSV Program has approved the start of Phase 3 of the pivotal clinical study of mRNA-1345, the vaccine candidate against respiratory syncytial virus (RSV), in adults 60 years and older.
The DSMB’s approval comes after an independent review of preliminary Phase 2 data, which indicates the vaccine has an acceptable safety profile in older adults at the selected dose. This study is known as ConquerRSV.
“RSV is one of the most prevalent respiratory viruses, causing serious illness and hospitalizations in the elderly, yet there is no vaccine available on the market,” said Stephane Bancel, CEO of Moderna.
‘We believe that our RSV vaccine candidate has the potential to protect against more than one million infections worldwide each year, improve the quality of life of those at high risk of infection and reduce burden on health care systems’.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
